Company Information

  

Address: FALKNERSTRASSE 4  
City: 4001 BASEL 
State:  
Zip Code: 00000 
Telephone: 41 (0)61 201 13 50 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders. Our most advanced product candidates are in Phase 3 clinical development. Keyzilen┬« (AM-101) is being developed for the treatment of acute inner ear tinnitus and has received fast track designation from the FDA. AM-111 is being developed for the treatment of acute inner ear hearing loss and has been granted orphan drug status by the FDA and the EMA and has been granted fast track designation by the FDA. AM-125 is being developed for the treatment of vestibular disorders. In addition, we are pursuing early stage projects for the treatment of tinnitus and rhinology. We believe we are currently the clinically most advanced company working on inner ear therapeutics.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
12/2016-0.89NAN/E
09/2016-0.89NAN/E
03/2016-0.90NAN/E
12/2015-0.92NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.24Total Liab/Total Assets0.60
Net Inc/Total Assets-0.86Total Liab/Inv Cap0.88
Net Inc/Inv Cap-1.25Total Liab/Comm Equity0.17
Pretax Inc/Net SalesNAInterest Coverage Ratio-36.17
Net Inc/Net SalesNACurr Debt/Equity0.16
Cash Flow/Net SalesNALTD/Equity0.73
SG&A/NetSalesNATotal Debt/Equity0.88
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio3.76
Inventory TurnoverNACurrent Ratio3.76
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  12/31/2016 12/31/2015 12/31/2014 3/31/2014
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 5.36 4.34 4.52 1.93
Operating Income -29.74 -30.85 -22.34 -6.63
Interest Exp 0.82 0.01 0.06 0.06
Pretax Income -30.30 -29.68 -18.30 -6.63
Other Income 0.25 1.18 4.09 0.06
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -30.17 -29.68 -18.30 -6.63

Balance Sheet (Millions)

Assets 12/31/2016 12/31/2015 12/31/2014 3/31/2014
Cash & Short Term Investments 31.92 50.19 57.30 20.98
Receivables - Total 0.29 0.65 0.55 0.66
Inventories - Total NA NA NA NA
Total Current Assets 33.15 51.02 58.11 21.64
Net Property, Plant & Equipment 0.36 0.22 0.24 0.30
Total Assets 35.08 52.76 59.87 23.62
Liabilities        
Accounts Payable 6.64 6.16 4.47 3.75
Debt in Current Liabilities 2.18 0.00 NA 0.00
Total Current Liabilities 8.81 6.16 4.47 3.75
Long-Term Debt 10.10 0.00 NA NA
Total Liabilities 21.17 8.06 6.25 4.51
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 13.51 13.71 11.68 8.53
Retained Earnings -110.54 -81.50 -52.46 -44.10
Treasury Stock NA NA NA NA
Total Stockholders' Equity 13.92 44.70 53.62 19.11
Total Liabilities and Stockholders' Equity 35.08 52.76 59.87 23.62

Cash Flow Summary (Millions)

Categories 12/31/2016 12/31/2015 12/31/2014 3/31/2014
Net Cash Provided by Operating Activities -28.98 -28.70 -19.44 -5.87
Net Cash Provided by Investing Activities -0.17 -0.04 -1.19 -0.06
Net Cash Provided by Financing Activities 11.25 20.90 49.93 -0.10

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-5.03--
12/20130.00-16.87--
12/20140.00-18.30--
12/20150.00-29.68-0.92
12/20160.00-30.17-0.89
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/172312,59527.34




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.